ArticleFrontiers in immunology2022
The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- [Value of direct immunofluorescence in the diagnosis of oral mucosal pemphigus vulgaris: A retrospective study based on multi-index combined analysis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- IgG subclasses and their significance in pemphigus disease progression monitoring.Frontiers in immunology · 2026Article
- The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database.Frontiers in immunology · 2025Article
- Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab.Frontiers in immunology · 2025Article
- Case Report: Dupilumab in difficult-to-treat bullous pemphigoid at the University Hospital Schleswig-Holstein, Campus Kiel.Frontiers in medicine · 2025Article
- Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence.The Journal of dermatology · 2024Review
- Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris.Acta dermato-venereologica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We studied the distribution and Methods: We longitudinally studied the distribution of anti-DSG3 IgG subclasses (before Results: Sixty-five sera were assessed at baseline (33 from patients treated with rituximab and 32 with corticosteroids). Sixty-three percent of these baseline sera contained 2 or more anti-DSG3 IgG subclasses Conclusion: The serum levels and number of anti-DSG3 IgG subclasses drive the pathogenic effect of pemphigus sera and may predict the occurrence of relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.